-
-
-
-
-
-
-
Denali Therapeutics and Royalty Pharma Announce $275 Million Royalty Funding Agreement
-
-
-
-
-
-
-
Denali Therapeutics Inc. (DNLI) Misses Q2 EPS by 1c
-
-
-
-
-
-
-
Denali Therapeutics Announces Initiation of BLA Filing for Accelerated Approval of Tividenofusp Alfa for the Treatment of Hunter Syndrome (MPS II) and Positive Ongoing Interactions with FDA on DNL126
-
-
-
-
-
-
-
Denali Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights
-
-
-
-
-
-
-
Denali Therapeutics Reports Second Quarter 2023 Financial Results and Business Highlights
-
-
-
-
-
-
-
Denali Therapeutics Announces Key Anticipated 2023 Milestones for Its Therapeutic Portfolio for Neurodegeneration and Lysosomal Storage Diseases
-
-
-
-
-
-
-
Denali Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Business Highlights
-
1,168,522 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

